Randox Food Diagnostics: Feed Testing in the Meat Industry ā Challenges and Solutions
Randox Food Diagnostics: Feed Testing in the Meat Industry ā Challenges and Solutions
The global meat industry is a multi-billion-dollar business contributing over $85 billion to the US economy alone annually. Globally it is valued at $800 billion and as such, it is one of the biggest industries in the world.
With its already strong position and an ever growing demand for meat products the market shows no sign of slowing down. There are continued demands set on producers to provide not only more meat, but meat at a higher quality. Public awareness on issues such as drug residues, animal rights, food safety and antibiotic resistance is on the rise and as such producers and processors are more and more required to meet stringent requirements.
With the increasing demand on quantity and quality the industry faces many challenges and one the key areas of interest in this production chain is the monitoring of residues.
Residues in food relates to the residual amount of a particular compound either administered to an animal as a veterinary treatment or a naturally occurring compound present in food for human consumption.
There are a number of potential issues that can arise from contaminated feed and it is important for producers to ensure that animal feed has little or no trace of residues of mycotoxins, growth promoters or veterinary drugs.
Veterinary drugs are often added to feed to be used as a method of treating livestock, producers therefore must be sure of the dosage to ensure that withdrawal periods are correctly adhered to. Mycotoxins may also be present in feed due to a number of environmental factors, this can have a negative impact of the livestock.
The Mycotoxin Threat
Mycotoxins are naturally occurring toxins produced by fungi, commonly known as moulds, which can have a harmful effect on humans and livestock. These moulds are of interest to producers because they have the potential for significant economic losses due to how they impact human health, animal productivity and international trading.
Mycotoxins can be present in a wide variety of foods and feeds and are a particular threat in areas with climates of high temperature and humidity. They can enter the food or feed chain through contaminated crops, in particular cereals, poultry meat and kidneys, pig kidneys and pork sausages. Contamination may also occur post-harvest during storage, transport, and processing stages of the food or feed supply chain.
The establishment of mycotoxin limits and regulations have been set by multiple food agencies worldwide. For example the EU 2002-32 Directive sets maximum permitted levels (MPLs) for substances that are present in, or on, animal feed that have the potential to pose danger to animal or human health, to the environment, or could have an undesirable affect to livestock production.
One type of livestock that can be significantly impacted by mycotoxins are pigs. Pig feed contaminated with mycotoxins can cause serious risks to pig health.
For example, Aflatoxins consumed by swine can expose non-clinical characteristics with low level exposure (20 to 200 ppb), inducing symptoms displayed such as feed avoidance, gastrointestinal disturbances, paleness and slower growth. It can also suppress the immune system and cause young piglets to become more susceptible to bacterial, viral or parasitic diseases. With prolonged exposure causing a greater risk of cancer, liver damage and jaundice. High concentrations of aflatoxin (1,000 to 5,000 ppb) result in acute effects, including death. It is a genotoxic carcinogen and suitably its levels have been set as low as realistically possible in complete feeding stuffs for pigs and poultry with a maximum content value of 0.02.
Zearalenone is another mycotoxin that can have a negative impact on livestock. Produced by a strain of Fusarium graminearum it has been listed under the Directive with a guidance value. It has an estrogeneous action and is significantly toxic to the reproductive system of animals with the potential to cause rectal and vaginal prolapses in gilts (young sows). Zearalenone has been allocated a suggested guidance value of 0.1ppm in complementary and complete feeding stuffs for piglets and gilts and 0.25ppm in feedstuffs for sows and fattening pigs.
With the risk from multiple Mycotoxins in animal feed it is important to be able to detect dangerous levels of each listed in the EU Directive in order to reduce instances of damage to animal health.
Growth Promoters
Growth promoters are often used in the meat industry to increase yield of livestock, an important tool considering the increased demand on quantity from the food chain. Some of these growth promoters however are known to have a negative impact on both animal and human health.
The presence of anabolic steroids including beta agonists such as Clenbuterol and Ractopamine, as well as other veterinary drugs is under a strict monitoring program in meat and animal feed to prevent these negative impacts.
Growth promoting drugs are used to induce weight but can have various health concerns such as such as hospitalisation with reversible symptoms of increased heart rate, muscular tremors, headache, nausea, fever, and chills.
The potential human health risks highlight the importance of complete food safety testing before a food product reaches the public.
Veterinary Drugs
Due to the nature of the conditions livestock is generally kept in, there is a high potential for infection and spread of viruses. Producers need to be aware and proactive in treating any veterinary disease that arises.
One such disease that can be an issue is coccidiosis which is a parasitic disease of the intestinal tract. This disease can be spread by contact with infected faeces, or the ingestion of infected tissues by other animals. Coccisiostats are potent drugs which are widely used within veterinary practice to treat coccidiosis, mainly in feed additives. Chickens are susceptible to at least 11 species of coccidia that causes coccidiosis therefore creating an importance to treat for. Coccisiostat residues that occur in high levels within food for human consumption can be unsafe and can have negative effects on pre-existing coronary conditions/diseases. These residues can pass through the meat tissue and eggs.
The Solution
With a variety of potential residues to be detected and a need for accurate results many producers are using Randox Food Diagnostics technology to carry out sample analysis.
With the development of the patented Biochip Array Technology Randox have consolidated the testing of multiple residues down to one sample which means time and cost saving for the meat industry. For example, with one Biochip a meat producer’s laboratory could test for 9 different growth promoter residues.
The technology centres on the Biochip, a 9mm2 ceramic chip which acts as the reaction well where samples are placed, requiring little technical expertise for preparation. Each chip is spotted with the antibodies required to detect the individual analytes being tested for and can accommodate up to 43 analytes. Food laboratories can then detect 43 different residues with one test.
The biochip works on the Evidence Investigator (Semi-Automated) and Evidence MultiSTAT(Automated) analysers. These analysers are used as the imaging stations for the biochips. Each spotted test site sends out a chemiluminescent signal which is detected by the analyser, processed, quantified and validated by the instrument software.
With a simple process, fast method and trusted results many of the world’s top meat producers are investing in Biochip Array Technology to ensure the safety and quality of their products.
For more information please contact us at: info@randoxfooddiagnostics.com.
RTS: Back-to-Lab Testing
Randox Testing Services offers high quality drug testing with use of our revolutionary Biochip Array Technology specifically optimised for drugs of abuse testing. This technology allows multiplex back-to-lab testing of different drugs from one sample and offers test consolidation for comprehensive testing at an affordable price.
With a comprehensive drugs of abuse test menu we are able to test for a range of different drugs. Drug testing packages can be customised to include multiple different drugs to test per sample.
Our drug testing methods ensure fast and simple sample collection. We have a variety of non-invasive methods for patient comfort including use of a urine sample, hair strand or oral fluid sample to test for specified drugs. Utilisation of different testing methods also ensures flexibility of drug abuse profiling with the ability to offer short-term drug abuse profiling via oral fluid and urine testing, long-term drug abuse profiling via hair testing or a combination of both.
Oral Fluid Testing
An oral fluid test can detect drugs for up to 48 hours after consumption. Providing analysis of short-term drug abuse, an oral fluid drug test is used by employers conducting for-cause and post-incident testing, as well as medico-legal solicitors who may require testing for abstinence of drugs.
An oral fluid test consists of obtaining a saliva sample from between the cheek and gums to analyse traces of drugs. This sample method is reliable due to the high concentrations of drug components which remain in the oral cavity for a period of time after drug consumption. Sample collection is taken quickly, easily and is non-invasive. The sample collection is also observed which ensures samples are not tampered with.
Urine Testing
A urine test offers short-term detection of substance abuse. Alcohol is detectable in urine for less than 12 hours, and a urine drug test can detect traces of drugs from between 4 hours and up to 8 days (this may be extended for regular cannabis users to around 30 days). It is often used in a combination with hair testing to provide an enhanced time-line for drug and alcohol detection; therefore allowing analysis of chronic substance abuse.
As a simple and practical method it is used as the most common sample type for workplace drug and alcohol testing. It is also utilised when conducting family law testing to ensure no alcohol intake by someone who has been forbidden to consume alcohol by a court of law or someone who is on a drugs or alcohol rehabilitation program.
A urine test consists of gaining a urine sample from the individual securely. Due to the nature of the urine sample being deposited privately by the sample donor, measures need to be taken to ensure the sample is not tampered with. At Randox Testing Services samples are collected under strict chain of custody protocols to guarantee sample integrity for legally defensible testing. We also increase accuracy of results by testing for creatinine which is a simple method of testing the authenticity of the sample given and reduces false-negative results giving you confidence in these testing methods.
Hair Testing
Hair testing is a long-term substance abuse profiling with a detection window of 90+ days. It is commonly used by recruiters and employers conducting pre-employment screening and is the most common sample type used for substance abuse assessment in child protection and medico-legal cases.
Hair testing involves taking a hair stand sample from an individual to detect if and approximately when someone has consumed drugs or alcohol. A 3cm sample is generally used to obtain a longer analysis of substance abuse.
When a drug is taken it is absorbed into the blood stream and circulated around the body. As a result it is incorporated into the hair follicle meaning that as the hair grows, drugs are transferred into the hair strand. It can take up to 2 weeks for drug components to enter the hair and therefore analysis of a 3cm sample is recommended.
Analysis of the hair strand allows traces of drugs to be detected to provide an overall picture of drug abuse or a month by month analysis. Segmentation of the hair sample to provide a detailed month-on-month view is advantageous as it can highlight trends of drug use and identify periods of abstinence or high level use. Body hair can be used in special circumstances however segmentation into a month by month analysis is not possible.
Randox Testing Services
Through utilising innovative multiplex drug and alcohol screening methods as well as LC/GC mass spectrometry confirmatory analysis our complete service guarantees reliable and accurate results.
For more information on our back-to-lab testing services contact us at testingservices@randox.com to speak with one of our experts.
Biotin Supplementation Interference in Health Diagnostic Testing
Continuing our theme of Biotin (Vitamin B7) this month, we turn our attention to its role in diagnostic testing.
With as many as 20% of people taking biotin-containing supplements, including high profile celebrities such as Kylie Jenner, Kim Kardashian and Vanessa Hudgens, it is important to know the effects it can have on particular blood tests, should you visit your GP or local hospital.
Whilst there are various diagnostic health tests out there, including fertility hormone tests, prostate tests, and tests for troponin – a marker released into the blood during a heart attack – that are known to be affected by elevated levels of biotin, there are other tests available, including those provided by Randox, that are not impacted.
The reason that so many non-Randox tests are impacted by biotin is that biotin is widely used throughout the biotechnology industry in the development of diagnostic tests.
ELISA tests in particular (tests that measure the reaction of antibodies to identify a substance) often make use of antibodies labelled with biotin, to detect toxins or other foreign substances within the body.
In most instances, the biotin will bind with high affinity to a protein called streptavidin. This affinity of streptavidin for biotin is the strongest non-covalent biological interaction known, and is therefore particularly useful in binding antibodies within diagnostic tests.
But with more and more people exceeding the recommended daily dosage for biotin (30 micrograms) by taking up to 10,000 micrograms of biotin in supplements marketed for beauty reasons, many diagnostic tests are being measured inaccurately. Excess biotin in the blood can block the binding of biotin-labelled antibodies to streptavidin within the tests, and the substance being tested won’t be measured accurately.
Laboratory professionals have known about this potential problem for some time. In late November 2017, the FDA (Food and Drug Administration) published a safety notice to make the public and healthcare practitioners more aware that biotin can “significantly interfere with certain lab tests and cause incorrect test results.”
The FDA even reported on one particular case in which a patient died following falsely low troponin (marker of a heart attack) results when the troponin test used was known to have biotin interference. Biotin supplements masked the true diagnosis of a heart attack.
Many patients taking biotin supplements have also been misdiagnosed with a condition called Graves’ disease, an autoimmune condition characterised by an overactive thyroid. In these cases, biotin supplementation led to falsely low levels of thyroid stimulating hormones, and falsely high levels of other thyroid hormones. This particular profile of hormones led to a Graves’ disease diagnosis, in spite of a lack of symptoms, which in Graves’ disease would usually include muscle weakness, a quickened heartbeat, sleeping problems, diarrhoea, weight loss and poor tolerance of heat.
In pregnant women, tests that are impacted by biotin interference may produce falsely low levels of beta HCG, more commonly known as the ‘pregnancy hormone’ as it released by the placenta after conception. With low levels of beta HCG, and therefore no confirmation of pregnancy, pregnant women could be exposed to X-rays and CT scans that may harm the developing foetus.
So, what can be done? Suggestions have been made that patients taking biotin supplements should be made to wait before any diagnostic testing is conducted, so that the biotin clears from their system.
But this “Wait and Watch” approach certainly would not work in emergencies. In the case of a heart attack, testing must be conducted as soon as possible to allow for diagnosis, immediate medical intervention and follow-up testing.
At Randox, we are convinced that the risk of analytic interference by biotin supplementation is a serious problem that needs to be more widely recognised and promptly addressed.
In the GP setting, general practitioners must ask their patients if they are taking any biotin supplements and inform the testing laboratory if interference from biotin is a possibility. They should also consider that lab results not matching with a patient’s signs and symptoms may be caused by biotin interference.
In the acute care setting however, it is imperative that biotin technology is not used in diagnostic testing to protect patients from misdiagnosis and subsequently, further health problems.
This is why Randox’s patented Biochip Array Technology does not use biotin technology in its development. This revolutionary methodology, free from Biotin-Streptavidin is not impacted by elevated levels of biotin from biotin supplementation in the same way as Biotin-Streptavidin tests.
So if you have been taking biotin supplements for hair or nail growth, to ease symptoms associated with Multiple Sclerosis, for epilepsy or for a range of other health conditions, and your diagnostic testing has been conducted using Randox Biochip Array Technology, you can rest assured of true, accurate, and reliable results.
Randox Biochip Array Technology is interference-proof.
For further information on the Randox Biochip, visit https://www.randox.com/multiplex-testing/
For any additional questions, please contact Randox PR by email: randoxpr@randox.com or by phoning 028 9442 2413
Antibodies & Human Recombinant Proteins
Randox Biosciences is a world-leading primary manufacturer of high quality monoclonal and polyclonal antibodies, antibody fragments and human recombinant proteins. Our team of scientists possess unrivalled expertise which enables us to provide you with a comprehensive suite of products and services dedicated to advancing biopharmaceutical research and diagnostics.
Product Portfolio
Randox Biosciences offers an extensive portfolio of over 900 products for a multitude of R&D applications including more than 500 monoclonal and polyclonal antibodies and over 140 human recombinant proteins as well as antibody fragments, buffers & diluents and plasma.
Monoclonal Antibodies
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; cardiovascular/cerebrovascular and metabolic/Nutrition
- Drugs of abuse: Alcohol, anti-depressants, barbituates, hallucinogens, opiates, stimulants
- Drug Residues: antimicrobial drugs, growth promoters, mycotoxins
Polyclonal Antibodies
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; Immunology, Oncology, Cardiovascular/Cerebrovascular and Metabolic/Nutrition
- Drugs of abuse: Alcohol, Analgesics, Anti‑depressants, Barbituates, Benzodiazepines, Hallucinogens, Opiates, Sedatives, Stimulants, Synthetic Drugs, Therapeutic drugs
- Drug Residues: Anti-inflammatory Drugs, Antimicrobial Drugs, Anti-Parasitic Drugs, Growth Promoters, Mycotoxins
Recombinant Antibody Fragments
- Single chain variable fragment (scFvs)
- Single domain antibodies (sdAbs)
Frozen Human Plasma
- Available in three formats (Male, Female and Mixed Gender)
- Highly screened for; HIV, Hepatitis B+C, HTLV I + II, Syphilis, CMV and Procleix WNV
Human Recombinant Proteins (E.Coli & Mammalian)
- Adhesion Molecules
- Chemokines
- Cytokines
- Proteases
- Tumour markers
Buffers & Diluents
- Complementary range available
Key Features & Benefits
- All products manufactured at our ISO 13485 accredited UK manufacturing plant
- Product range of over 900 products
- 30 years’ experience in raw material manufacture and assay development
- Many unique and novel products including designer drugs, Mycotoxins and oncology markers
- As our host animals are sheep, our antibodies have higher sensitivity and specificity
- Excellent reproducibility between lot numbers
- Products reflect the components used in-house in the production of Randox diagnostic products and research programs
- Highly experienced in developing difficult targets (i.e. small molecules and novel biomarkers)
- Full customisation service available
- A range of pack sizes available including bulk quantities for commercial development
- Products can be used in a multitude
Custom Development Services
To meet your precise requirements, Randox Biosciences offer customised antibody generation services to the pharmaceutical and biotechnology industry. Our custom development service, which encompasses antibodies and human recombinant proteins has achieved tremendous success within the biopharmaceutical and diagnostic industries. Key components of our custom service are our range of monoclonal antibodies as well as our recombinant antibody fragments (sdAbs, scFvs, fAbs).
Our customisation service has proven incredibly successful in the research and development industries allowing access our expertise to obtain the antibody and protein most relevant to your line of work. With over 300 highly trained research scientists and over 30 years’ experience in commercial assay development, Randox Biosciences can also provide a tailor-made assay development service to meet your specifications in both a timely and cost-effective manner.
For more information contact: info@Randoxbiosciences.com
Health Theme August 2018: The role of Biotin / Vitamin B7
How much do you know about Biotin? Taken by a wealth of celebrities including Kylie Jenner, Kim Kardashian and Vanessa Hudgens for its hair and nail-strengthening properties, this vitamin has grown in popularity in recent years.
Commonly known as Vitamin B7, Biotin is a water-soluble vitamin found in bodily enzymes which metabolise fat and carbohydrates.
It therefore plays an important role in cell growth and in maintaining a steady blood sugar level, and also assists in various reactions, including the movement of carbon dioxide around the body. It is often recommended as a dietary supplement for strengthening hair and nails, and as such is often found in many cosmetics and health products for the hair and skin.
Due to its key role within the body, the National Academy of Medicine (formerly the Institute of Medicine) recommends a dose of 30 micrograms of biotin each day, from a range of food sources including beef or pork, egg, yeast, whole wheat bread, avocado, salmon, cauliflower or cheese. Raw egg whites however contain a particular protein that blocks the absorption of biotin, so people who regularly consume a large number of eggs may become biotin-deficient.
Those suffering from biotin deficiency disorders therefore are often prescribed biotin supplements – up to as much as 300 milligrams per day for Multiple Sclerosis patients, for whom the B group vitamins are vital in managing symptoms. Biotin in particular is very useful in cases of progress MS because it supports nerve cell metabolism.
There are also some inherited metabolic disorders which, due to a deficiency in the enzymes which process biotin, prevent the body’s cells from using it effectively.
Usually, however, biotin deficiency occurs simply from an absence of the vitamin in the diet, particularly in breastfeeding mothers. Symptoms of deficiency include:
- Conjunctivitis
- Dermatitis in the form of a scaly red rash
- Neurological symptoms in adults including depression, lethargy, hallucination, numbness and tingling of the extremities
- Brittle and thin fingernails
- Hair loss (alopecia)
Supplements may also be recommended to those suffering from alcoholism, patients who have had partial removal of their stomach, burn patients, epileptics, elderly individuals, athletes, and pregnant women, who have a higher risk of biotin deficiency. It is estimated that as many as 20% of people consume Biotin-containing supplements.
While biotin supplements may help pregnant women and some people with other health disorders, it is of course incredibly important to eat a balanced and healthy diet that includes all the vitamins and minerals necessary for normal body function.
Take time to consider how you can incorporate appropriate and safe amounts of biotin into your daily diet.
For further information, please contact Randox PR by email: randoxpr@randox.com or by phoning 028 9442 2413
The Correlation Between Liver Cirrhosis and Lactic Acidosis
Lactic acid is an organic compound which produces the conjugate base lactate through a dissociation reaction. Due to it being a chiral compound, two optical isomers of lactate exist; D-Lactate and L-Lactate. The lactate dehydrogenase (LDH) enzyme can produce and metabolise both isomer forms to pyruvate, however due to the isomer-specific nature of LDH different forms of the enzyme are required. D-Lactate requires a D-LDH form whereas L-Lactate requires L-LDH. As a result of this requirement, combined with the fact that mammalian cells only contain L-LDH, the lactate produced in humans is almost exclusively L-Lactate.
One of the roles of L-Lactate is its involvement in the Cori Cycle, a metabolic pathway involved in the production of glucose. The cycle involves the rotatory transportation of lactate and glucose from the liver and the muscle. Lactate is produced in the muscle through glycolysis which is then transported to the liver through the blood stream. In the liver, the lactate is oxidised to pyruvate and then converted to glucose by gluconeogenesis, which is then transported back to the muscle for the process to start again. 1500 mmol of lactate is produced daily by the body and is cleared at a constant rate via the liver.
Problems can arise if the liver fails to regulate the lactate produced. Hyperlactamia is the name given to elevated levels of lactate in the body, as a result of the rate of production exceeding the rate of disposal. This is due to a lack of oxygen that reduces blood flow to the tissues. If levels continue to rise a patient is at risk of lactic acidosis.
The liver is an important tissue in the regulation of lactate, it is therefore no surprise that liver damage can prevent this process resulting in a further diagnosis of lactic acidosis. A healthy liver is a vital part of lactate regulation as it acts as the main consumer of lactate and contributes to 30-40% of lactate metabolism. Potential victims are patients who suffer with cirrhosis, a complication of liver disease, which is commonly caused by alcohol abuse and viral Hepatitis B and C.
Patients with liver cirrhosis have a higher risk of increased lactate levels. Increased levels of the lactate ions disturbs the acid-base equilibrium, causing a tilt towards lactic acidosis. The mortality rate of patients who develop lactic acidosis is high, prompt recognition and treatment of the underlying cause remain the only realistic hope for improving survival.
The Randox L-Lactate reagent allows for a prompt and accurate diagnosis of lactic acidosis.
Randox L-Lactate Reagent
The Randox L-Lactate key benefits include:
- Excellent working reagent stability of two weeks when stored at + 15 – +25°C
- Exceptional correlation of r = 0.99 when compared against other commercially available methods
- A wide measuring range of 0.100 – 19.7 mmol/l and so is capable of detecting abnormal levels in a sample
Other features:
- Colorimetric method
- Lyophilised reagents for enhanced stability
Sri Lanka taking measures to tackle the opium abuse crisis
Cannabis continues to be the most reported drug abused in Sri Lanka, however cannabis related offences have decreased from 66.2% to 61.9% in April – May 2018. Heroin is the second highest drug abused at 28.8% of those arrested in April and 35.9% of arrestees in May engaging in heroin related offences. Hashish, babul, madana modaka, opium, methamphetamine and tablets are other prevalent drugs abused in Sri Lankan drug related offences that have been noted. Although cannabis related crime has decreased, drug prevalence and drug related offences are increasing in the country.
Sri Lanka has been taking measures to tackle the abuse of opium, cannabis and certain psychotropic substances since its independence in 1948. Opium is not cultivated in Sri Lanka, however over the past decade Sri Lanka has been used as a trans-shipment point for heroin from South West Asia and India to other destinations outside of the subcontinent. Heroin seized prior to reaching Sri Lanka is roughly two – three times the quantity of heroin seized in Sri Lanka itself.
Randox Toxicology are the leading manufacturer of the patented Biochip Array Technology (BAT). BAT is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. After the addition of a sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
Additionally, our range of immunoanalysers include the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT which individually utilise our Biochip Array Technology for the screening of drugs of abuse. Our extensive toxicology test menu covers a broad range of classical, prescription, synthetic drugs and new psychoactive substances. With multiple matrices available, Randox Toxicology are a global leader in the Toxicology market.
Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our DoA II panel can detect opium and generic opioids. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends.
To find out more about the DoA II panel and our other available test menus, email info@randoxtoxicology.com or visit randoxtoxicology.com.
Nutritional status: copper deficiency
Did you know that copper is an essential trace mineral present in all tissues? It works with iron to help the body form red blood cells. It also helps keep the blood vessels, nerves, immune system and bones healthy while also aiding in iron absorption. In rare situations, copper deficiency can occur and lead to anaemia and osteoporosis.
Symptoms of copper deficiency include:
- Fatigue & weakness as cells use copper to generate ATP, the body’s main source of energy. This means that copper deficiency could affect your energy levels.
- Frequent sickness as copper plays an important role in maintaining a healthy immune system.
- Weak and brittle bones as copper is involved in the processes that create cross-links inside your bones. These cross-links ensure bones are healthy and strong.
- Problems with memory and learning as copper plays an important role in brain function and development.
Sensitivity to cold as copper, along with minerals like zinc, help maintain optimal thyroid gland function. Low thyroid levels can make you feel colder more easily.
There are many foods that are high in copper. These include leafy greens, including turnip, greens, spinach, kale and mustard greens. Asparagus and summer squash are two other excellent sources of copper while legumes, whole grains, nuts and seeds are also good sources of the substance.
Randox Reagents, RX and QC are helping to diagnose copper deficiency at the earliest possible stage. The Randox copper assay is used to measure the levels of copper in the blood in order to determine copper toxicity. Combining this with the Randox zinc assay can aid in identifying the cause of liver damage in a patient, leading to correct treatment and recovery.
Find out more about how Randox is helping to diagnose nutritional status and deficiencies here: https://www.randox.com/nutritional-status/
The Issues Surrounding Drug Residues in the Global Food Market
The potential presence of drug residue contaminants in food products destined for human consumption is an increasingly popular topic of conversation in the industry but what are the main challenges facing the industry to tackle this potential issue?
Drug residue contaminants in food products is a discussion that involves the global community but each individual country or trade bloc has their own protocols and regulations relating to the control and monitoring of residues. The different legislations are designed to protect the general public as well as the food industry interests in their individual countries. Any business that wishes to sell their products within other countries or regions must meet their legislative requirements relating to drug residues. These differences in regulations have increased the need for increased dialogue on the issue as well as the implementation of effective monitoring systems.
The industry must deal with the potential of residues from antibiotics and growth promoting hormones entering the food chain. This will involve ensuring correct dosage per animal and also adhering to withdrawal periods set for their region. The second issue the industry faces is the stigma received from the misuse of these antibiotics and growth promoting hormones.
While there is a potential for misuse it should always be noted that a producer’s main concern should always be animal health, which leads to a quality end product. The use of antibiotics is to ensure the health of the animal and to reduce the potential knock on effect of untreated diseases which could create a downturn on yield. Growth promoting hormones are used to increase this yield also but should never be done so at the expense of a safe end product.
Residues from particular drugs in food produce can have serious implications for human health. As such many countries have set Maximum Residue Limits (MRLs) or tolerances for these residues in food. The Maximum Residue Limit is the maximum concentration of a residue that can be present in a product from an animal or animal by product intended for the food supply. These MRLs mean that it is required by law in the enforcing countries that any product in the food chain cannot contain residue levels that are harmful to human health above these limits.
There has been controversy over measures to tackle drug residues in foods as there are no internationally accepted standards for many drugs. Ractopamine in particular has caused trade disputes as it is permitted in food production in some countries like the US & Canada, but the European Union, China, Taiwan and over 100 other countries have banned its use.
The real challenge the food industry faces is ensuring their testing methods are effective and reliable to ensure the safety of a variety of end products. To name a few of these diverse products we can look at the dairy, meat, seafood, feed and honey markets.
Dairy Market
The dairy industry is under constant scrutiny and pressure to constantly produce high volumes of milk whilst maintaining a superior standard of quality in their dairy products. As part of the production process various contaminants are administered to cattle in an effort to systematically treat various infectious diseases and maintain a healthy herd. A direct consequence of this is the requirement of routine monitoring and testing within farms and dairy processors to ensure that the levels of contaminants in milk are within legal regulations not exceeding Maximum Residue Limits and that unauthorised substances are not found at any level in milk.
Testing can be conducted at several points during the production process. Firstly, farm level testing can be carried out to screen milk from cows that have been separated from the herd and undergone antibiotic treatment. Secondly, the dairy processor is required to conduct testing both onsite taking samples from tankers and retrospective testing as a method of internal surveillance to ensure the milk supplied from several farms is within global regulatory limits. Thirdly, retailers can test the processed milk end product to guarantee the milk is antibiotic free before it’s added to supermarket shelves for consumers.
Meat Market
Global meat production and consumption have increased rapidly in recent decades. Worldwide meat production has tripled over the last four decades and increased 20 percent in just the last 10 years. Meanwhile, industrial countries are consuming growing amounts of meat, nearly double the quantity in developing countries. Mass quantities of antibiotics are used on livestock to reduce the impact of disease, contributing to antibiotic resistance in animals and humans alike. Worldwide, 80 percent of all antibiotics sold in 2009 were used on livestock and poultry, compared to only 20 percent used for human illnesses.
Growth promoters, which are tested for under the NRCP, are hormonal and antibiotic substances that may be used in food producing animals for growth promotion in livestock animals thus increasing the production of muscle meat and the reduction of fat. The type of growth promoter used is dependent on the animal species and mode of rearing with steroid growth promoters used for beef cattle and antibiotic growth promoters, which are usually added to feedstuffs, such as the coccidiostats used in the poultry industry and chlortetracycline used in the porcine industry. The rapid speed of meat production calls for the need to test for drug residues frequently to prevent them from ending up in the food chain.
Seafood Market
The global aquaculture industry has grown steadily over the past five decades, increasing at an average rate of 3.2%. However, this growth has come at a cost, with the industry facing many new challenges. Farmed seafood is often treated with medicated feeds which contain antibiotics such as leucomalachite green and nitrofurans for example to prevent from disease spreading, they are also exposed to other harmful residues used to treat algae etc. within the ‘pens’ where they are kept.
The FAO (2012) reported that 38% of fish produced globally is exported, highlighting the imbalances in regional supply and the changing tastes of the global consumer. This increased level of exporting and importing shows the importance of drug residue screening within the global aquaculture industry. This increased level of exporting and importing shows the importance of drug residue screening within the global aquaculture industry.
Feed Market
The global animal feed processing market is estimated at US$21.61 billion in 2018 and is projected to reach US$ 26.62 Billion by 2023. The market is driven by factors such as the rising awareness of feed nutrition and health, technological advancements in the equipment industry and increase in the demand for feed around the world. Medicated feeds containing veterinary are often used to help prevent disease within livestock and there are MRLs for feed which has created the need for testing as high levels of residues can have an effect on livestock health and also transfer through to meat products for human consumption. With humidity levels rising in recent years there has been an influx in the level of mycotoxins found within feed and cereals. These toxins are fungal and can affect both livestock and human health for example mycotoxicoses which is a disease which can affect the respiratory system. The main cause of mycotoxins within stored grains are when the grain is damp or cracked and kept in insufficient storage conditions. These factors have made it necessary for feed and cereals to be tested for both drug residues and mycotoxins to ensure that they do not end up within the food chain.
Honey Market
The global honey market is growing at a rapid pace and the global consumption of honey is to reach 2.5 million tones by 2022. This growth is driven for consumers demand for natural and healthy alternatives to artificial sweeteners over cane sugar. There is also a growing awareness of the health and healing benefits of honey which is driving the demand for the use of honey for medicinal use, manuka honey sales continue to grow for its antibacterial and anti-inflammatory properties. The rapid rise in demand for honey outweighs the amount that can be produced in a natural form globally due to a decline in the number of bees. This has influenced the quality of honey being produced as some producers take to diluting natural honey with high-fructose corn syrups in order to supply the demand. There is a requirement for keepers to treat bee colonies with antibiotics to prevent CCD and other diseases such as varroa mites and there is a chance that these harmful drug residues can be transferred through to the end product ‘natural’ honey. The use of antibiotic drugs in apiculture is globally restricted and there are no MRLs set for antibiotics in honey as it a natural product and needs to be antibiotic free, this has cause the need for testing both for drug residues and the overall quality of the honey being produced.
Detection
Due to the requirement to use a variety of drug treatments in the food industry and also the potential economic benefits to be gained from the use of growth promoters, there will continue to be use in animal production. However, as analytical methods of detection become more sensitive, producers are given further options for testing.
The surveillance for the potential presence of these residues of veterinary substances is regulated by the EU Directive 86/469/EEC. This directive outlines the guidelines for sampling and testing within a residue monitoring programme.
The requirement to meet these standard and the MRLs and detection levels outlined in the legislation has created a need for analytical methods to become more sensitive to ensure correct analysis. On some occasions MRL’s have been lowered which require a technology sensitive enough to detect very low concentrations in a sample.
One such screening method that is commonly used is the Enzyme-linked immunosorbent assay (ELISA) methods, which work well for testing and providing accurate results.
Randox Food have developed another method of analysis using the Evidence Investigator which uses similar methodology to ELISA methods. The analyser uses biochip array technology (BAT) to perform simultaneous quantitative detection of multiple analytes from a single sample and can be used across multiple matrix types including the products produced by the industries mentioned. The core technology is the Randox biochip, this contains an array of discrete test regions containing immobilized antibodies specific to the drug residues under test.
These methods are rapid, reliable, and sensitive so are able to detect residues in very small concentrations. The Randox methods are developed in line with EU Directive 86/469/EEC and as such are an effective testing method for multiple areas of the food industry.
For further information please contact the Randox Food Diagnostics team by emailing: info@randoxfood.com
Securing the future with in vitro diagnostic tests
The aim of Biomedical Science Day is to raise the public’s awareness of the importance of biomedical science and the vital role it plays in the world. Randox are dedicated to improving healthcare worldwide through placing a major focus on research and development. The Randox scientists work in pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.
A recent blog from Doris-Ann Williams, the Chief Executive at BIVDA, explains how “increased funding is not enough to sustain the NHS” and how “we need to make better use of in vitro diagnostics to ensure a successful future”.
The National Health Service (NHS) is a publicly funded, primarily taxation, national healthcare system in the United Kingdom. It was first set-up on July 5th, 1948 by Aneurin Bevan as he believed that everyone, regardless of wealth, should have access to good healthcare. Whilst the NHS is an extremely important aspect of healthcare in the UK, in vitro diagnostics are the heart and soul of the healthcare system as healthcare professionals not only rely on blood tests to diagnose and treat patients, but also to rule out the different contributing causes to a disease state. In vitro diagnostics also plays a key role in monitoring chronic disease states. In vitro diagnostics can also aid in reducing hospital stays, reduce misdiagnosis and support patients in looking after their own health and to deliver personalised treatment plans.
The Randox scientists have developed several niche assays to improve patient diagnosis, monitor treatment and eliminate misdiagnosis.
Adiponectin
Adiponectin is a protein hormone secreted by adipocytes with anti-inflammatory and insulin-sensitising properties. It plays an important role in a number of metabolic processes including glucose regulation and fatty acid oxidation. Adiponectin levels are inversely correlated with abdominal visceral fat which have proven to be a strong predictor of several pathologies, including: metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD). For more information on the importance of testing Adiponectin levels, check out our Adiponectin Whitepaper.
Cystatin C
Cystatin C is an early risk marker for renal impairment. The most commonly run test for renal impairment is Creatinine. Creatinine measurements have proven to be inadequate as certain factors must be taken into consideration, including age, gender, ethnicity etc. The National Institute for Health and Care Excellence (NICE) have updated their guidelines, which now recommends Cystatin C as a more superior test for renal impairment due to its higher specificity for significant disease outcomes than those based on Creatinine. For more information on the importance of testing Cystatin C levels, check out our Cystatin C Whitepaper.
Small-dense LDL Cholesterol (sdLDL-C)
LDL Cholesterol (LDL-C) consists of two parts: the large and buoyant LDL Cholesterol and the small and dense LDL Cholesterol. Whilst all LDL-C transports triglycerides and cholesterol to bodily tissues, their atherogensis varies according to their size. As sdLDL-C is small and dense, they can more readily permeate the arterial wall and are more susceptible to oxidation. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction. It has been noted that sdLDL-C carries less Cholesterol than large LDL, therefore a patient with predominately sdLDL-C particle may require nearly 70% more sdLDL-C particles to carry the same amount of cholesterol as the patient with predominately LDL-C particles. For more information on the importance of testing sdLDL-C levels, check out our sdLDL-C Whitepaper.
These three niche in vitro diagnostics tests developed by Randox scientists can aid in reducing NHS costs due to their higher performance compared to the traditional tests. Randox are constantly striving to improve healthcare worldwide.
For more information on the extensive range of Randox third-party in vitro diagnostic reagents, visit: https://www.randox.com/diagnostic-reagents/ or contact reagents@randox.com.